fosfomycin/metronidazole/granulocyte macrophage colony stimulating factor (RNX-041) / Reponex Pharma - LARVOL DELTA

A combined treatment with GM-CSF, fosfomycin and metronidazole for pouchitis in ulcerative colitis patients after restorative ileal pouch anal anastomosis surgery. A clinical safety and proof-of-concept study (clinicaltrialsregister.eu) - P1/2 | N=18 | Recruiting | Sponsor: Region Sjaelland, Reponex Pharmaceuticals A/S | Not yet recruiting ➔ Recruiting

Enrollment open • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

Encouraging preliminary data from the first part of a clinical study in pouchitis (GlobeNewswire) - P1/2 | N=26 | "The safety and efficacy of endoscopically administered gel formulation of Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) is being evaluated in patients with pouchitis. The clinical safety and proof-of-concept study (EudraCT no: 2020-000609-10) assesses the combined treatment with GM-CSF, fosfomycin and metronidazole for pouchitis in ulcerative colitis patients after restorative ileal pouch anal anastomosis (IPAA) surgery."

P1/2 data • Inflammatory Bowel Disease • Ulcerative Colitis